A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS).
Yoshikawa
Takaki
T
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahi-Ku, Yokohama, Japan. yoshikawat@kcch.jp
Tsuburaya
Akira
A
Morita
Satoshi
S
Kodera
Yasuhiro
Y
Ito
Seiji
S
Cho
Haruhiko
H
Miyashita
Yumi
Y
Sakamoto
Junichi
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D013505:Digestive System Surgical Procedures; D004338:Drug Combinations; D006801:Humans; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel; D002945:Cisplatin